Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 18/20 | 0.68 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656536 | 0.88 | NPY5R (0.68) | NPY5R | |
| SCHEMBL4576310 | 0.81 | NPY5R (1.00) | NPY5R | |
| SCHEMBL4577444 | 0.78 | AVPR1A (0.58) | NPY5R | |
| SCHEMBL6054850 | 0.75 | AVPR1A (0.55) | NPY5R | |
| SCHEMBL6054826 | 0.74 | AVPR1A (0.56) | NPY5R | |
| SCHEMBL13606217 | 0.72 | CNR2 (0.51) | — | |
| SCHEMBL2657710 | 0.71 | NPY5R (0.64) | NPY5RDGAT1SIGMAR1 | |
| SCHEMBL10146443 | 0.71 | DGAT1 (0.87) | NPY5RDGAT1 | |
| SCHEMBL6054920 | 0.70 | NPY5R (0.64) | NPY5RSIGMAR1 | |
| SCHEMBL4577476 | 0.70 | NPY5R (0.55) | NPY5RDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1635813-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | Merck & Co. Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1635773-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000217-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | claimed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1635832-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635813-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | Merck & Co. Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635773-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000217-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |